Skip to main content

Research Repository

Advanced Search

Exploring the Prevalence of Clozapine Phenotypic Poor Metabolizers in 4 Asian Samples: They Ranged Between 2% and 13%

Ruan, Can-Jun; Wang, Chuan-Yue; Tang, Yi-Lang; Lin, Shih-Ku; Lee, Seung-Tae; Hong, Kyung Sue; Rajkumar, Anto P.; Jacob, Kuruthukulangara S.; De Leon, Jose

Authors

Can-Jun Ruan

Chuan-Yue Wang

Yi-Lang Tang

Shih-Ku Lin

Seung-Tae Lee

Kyung Sue Hong

Kuruthukulangara S. Jacob

Jose De Leon



Abstract

Purpose/Background: Clozapine clearance is influenced by sex, smoking status, ethnicity, co-prescription of inducers or inhibitors, obesity and inflammation. In 126 Beijing inpatients, we measured repeated trough steady-state serum concentrations and identified 4% (5/126) who were phenotypical poor metabolizers (PMs); none were ultrarapid metabolizers (UMs). They were defined as being 2 standard deviations beyond the means of total clozapine concentration/dose ratios stratified by sex and smoking. Using this definition, this study explores the prevalences of PMs and UMs using data from 4 already-published Asian samples. Three samples were East Asian (Beijing 2, Taipei and Seoul); one was from South India (Vallore).

Findings/Results: The prevalence of phenotypical PMs ranged from 2-13%, but inflammation was not excluded. The prevalence was 7.3% (14/191) for Beijing 2, 11% (8/70) for Taipei, 13% (9/67) for Seoul, and 2% (2/101) for the Vellore sample. Five phenotypical PMs appeared to be associated with extreme obesity. Phenotypic UM prevalence ranged from 0-1.6%, but may be partly explained by lack of adherence. A Vellore phenotypic UM appeared to be associated with induction through high coffee intake.

Implications/Conclusions: Around 10% of Asians may be clozapine PMs and may only need 50-150 mg/day to get therapeutic concentrations. Future studies combining gene sequencing for new alleles with repeated concentrations and careful control of confounders including inhibitors, inflammation and obesity should provide better estimations of the prevalence of phenotypic clozapine PMs across races. Clozapine UM studies require excluding potent inducers, careful supervision of compliance in inpatient settings and multiple serum concentrations.

Citation

Ruan, C., Wang, C., Tang, Y., Lin, S., Lee, S., Hong, K. S., …De Leon, J. (2019). Exploring the Prevalence of Clozapine Phenotypic Poor Metabolizers in 4 Asian Samples: They Ranged Between 2% and 13%. Journal of Clinical Psychopharmacology, 39(6), 644-648. https://doi.org/10.1097/JCP.0000000000001125

Journal Article Type Article
Acceptance Date Aug 19, 2019
Online Publication Date Nov 1, 2019
Publication Date 2019-11
Deposit Date Sep 5, 2019
Publicly Available Date Nov 2, 2020
Print ISSN 0271-0749
Electronic ISSN 1533-712X
Publisher Lippincott, Williams & Wilkins
Peer Reviewed Peer Reviewed
Volume 39
Issue 6
Pages 644-648
DOI https://doi.org/10.1097/JCP.0000000000001125
Public URL https://nottingham-repository.worktribe.com/output/2571498
Publisher URL https://journals.lww.com/psychopharmacology/Abstract/2019/11000/Exploring_the_Prevalence_of_Clozapine_Phenotypic.19.aspx

Files




You might also like



Downloadable Citations